References

Amery WK (1999) Signal generation from spontaneous adverse event reports. Pharmacoepidemiology and Drug Safety 8: 147-50.

Auriche M (1985) Approache bayesienne de l'imput-abilite des phenomenes indesirables aux medicaments. Therapie 40: 301.

Begaud B (1984) Standardized assessment of adverse drug reactions: the method used in France. Drug Inf J 18: 275-81.

Begaud B, Moride Y, Haramburu F (1994) Quality improvement and statistical calculations made on spontaneous reports. Drug Inf J 28: 1187-95.

Begaud B, Royer RJ (1986) The regulatory perspective. Drug Inf J 20: 409-12.

Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepat 11: 272-6.

Benichou C, Celigny PhS (1991) Standardization of definitions and criteria of causality assessment of adverse drug reactions. Int J Clin Pharmacol Ther Tox 29: 75-81.

Blanc S, Leuenberger P, Berger JP, Brooke EM, Schelling JL (1979) Judgements of trained observers on adverse drug reactions. Clin Pharmacol Ther 25: 493-8.

Blum MD, Graham DJ, McCloskey CA (1994) Tema-floxacin syndrome: review of 95 cases. Clin Inf Dis 18: 946-50.

Busto U, Naranjo CA, Sellers EM (1982) Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol 13: 223-7.

Case B, Oszko MA (1991) Use of an algorithm to evaluate published reports of adverse drug reactions. Am J Hosp Pharm 48: 121-2.

Clark JA, Klincewicz SL, LaFrance NL (2000) A Bayesian method for the evaluation of case series of adverse reactions (Abstr). Pharmacoepidemiology and Drug Safety 9 (Suppl): S33.

Clark JA, Klincewicz SL, Stang PE (2001) Spontaneous adverse event signaling methods: classification and use with health care treatment products. Epidemiol Rev 23: 191-210.

Clark JA, Zimmerman HJ, Tanner LA (1990) Labetalol hepatotoxicity. Ann Int Med 113: 210-3.

Cluff LE, Thornton GF, Seidl LG (1964) Studies on the epidemiology of adverse drug reactions. I. Methods of surveillance. J Am Med Assoc 188: 976-83.

Code of Federal Regulations (US), Section 312.32.

Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46: 1323-30.

Edwards IR, Lindquist M, Wiholm BE, Napke E (1990) Quality criteria for early signals of possible drug reactions. Lancet 336: 156-8.

Emanueli A, Sacchetti G (1980) An algorithm for the classification of untoward events in large scale clinical trials. Agents Actions 7: 318-22.

European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (1995) ICH Topic E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP / ICH/377/95). London: EMEA, p. 2/10.

European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (1997) ICH Topic E2C: Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (CPMP/ICH/288/95) London: EMEA, pp. 6/22, 15/22-17/22.

Food and Drug Administration (FDA), Center for Drugs and Biologics (1987) Reports Evaluation Branch Manual. Rockville: FDA, pp. 23 -23a.

Finney DJ (1963) An international drug safety program. J New Drugs 3: 262-5.

Freilich WB (1984) Legal perspectives in causality assessment. Drug Inf J 18: 211-7.

Frick PA, Cohen LG, Rovers JP (1997) Algorithms used in adverse drug event reports: a comparative study. Ann Pharmacother 31: 164-7.

Funch D, Dreyer NA, Bassin LG, Crawley JA, Brickley MG, Walker AM (1993) The validity of case reports in a pharmacoepidemiology study. Post Marketing Surveillance 7: 283-9.

George JN, Raskob GE, Shah SR, Rizvima MA, Hamilton SA, Osborne S, Vondracek T (1998) Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Int Med 129: 886-90.

Ghajar BM, Lanctot KL, Shear NH, Naranjo CA (1989) Bayesian differential diagnosis of a cutaneous reaction associated with the administration of sulfo-namides. Semin Dermatol 8: 213 -8.

Greenland S, Rothman KJ (1998) Measures of effect and association. In: Rothman KJ, Greenland S, eds., Modern Epidemiology. Philadelphia: LippincottRaven, pp. 51 -6.

Grohmann R, Dirschedl P, Scherer J, Schmidt LG, Wunderlich O (1985) Reliability of adverse drug reaction assessment in psychiatric inpatients. Eur Arch Psychiatr Neurol Sci 235: 158-63.

Hartmann K, Ciorciaro C, Kuhn M (1997) Signal generation in a non-EU country. Pharmacoepidemiology and Drug Safety 6 (Suppl 3): S13-S19.

Hoskins RE, Manning S (1992) Causality assessment of adverse drug reactions using decision support and informatics tools. Pharmacoepidemiology and Drug Safety 1: 235-49.

Hutchinson TA (1986) Standardized assessment methods for adverse drug reactions: a review of previous approaches and their problems. Drug Inf J 20: 43944.

Hutchinson TA, Flegel KM, HoPingKong H, Bloom WS, Kramer MS, Trummer EG (1983) Reasons for disagreement in the standardized assessment of suspected adverse drug reactions. Clin Pharmacol Ther 34: 421-6.

Hutchinson TA, Lane DA (1989) Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol 42: 5 -16.

Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. J Am Med Assoc 242: 633-8.

Inman B (1993) 30 years in postmarketing surveillance. A personal perspective. Pharmacoepidemiology and Drug Safety 2: 239-58.

Inman WHS, Mushin WW (1974) Jaundice after repeated exposure to halothane: an analysis of reports to the Committee on Safety Of Medicines. Br Med J1: 5-10.

Irey NS (1976a) Tissue reactions to drugs. Am J Path 82: 616-47.

Irey NS (1976b) Adverse drug reactions and death: A review of 827 cases. J Am Med Assoc 236: 575 -8.

Jones JK (1982) Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Comm Health 5: 58-67.

Jones JK (1987) A Bayesian approach to causality assessment. Psychopharm Bull 23: 395-9.

Jones JK (1994) Determining causation from case reports. In: Strom BL, ed., Pharmacoepidemiology, 2nd edn. New York: Wiley, pp. 365-78.

Karch FE, Lasagna L (1977) Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 21: 247-54.

Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L (1976) Adverse drug reactions: a matter of opinion. Clin Pharmacol Ther 19: 489-92.

Koch-Weser J, Greenblatt DJ (1976) The ambiguity of adverse drug reactions (Abstr). Clin Pharmacol Ther 19: 110.

Koch-Weser J, Sellers EM, Zacest R (1977) The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 11: 75-8.

Kramer MS (1986) Assessing causality of adverse drug reactions: global introspection and its limitations. Drug Inf J 20: 433-7.

Kramer MS (1988a) Clinical Epidemiology and Biosta-tistics. New York: Springer-Verlag, pp. 266-7.

Kramer MS (1988b) Clinical Epidemiology and Biosta-tistics. New York: Springer-Verlag, pp. 201-19.

Kramer MS (1988c) Clinical Epidemiology and Biosta-tistics. New York: Springer-Verlag, pp. 220-35.

Kramer MS, Lane DA (1992) Causal propositions in clinical research and practice. J Clin Epidemiol 45: 639-49.

Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. J Am Med Assoc 242: 623-32.

Lanctot KL, Naranjo CA (1995) Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 58: 692-8.

Lane DA (1984) A probabilist's view of causality assessment. Drug Inf J 18: 323-30.

Lane DA (1986a) The logic of uncertainty: measuring degree of belief. Drug Inf J 20: 445-53.

Lane DA (1986b) The Bayesian approach to causality assessment: an introduction. Drug Inf J 20: 45561.

Lane DA, Kramer MS, Hutchinson TA, Jones JK, Naranjo C (1987) The causality assessment of adverse drug reactions using a Bayesian approach. Pharma-ceut Med 2: 265-83.

Leventhal JM, Hutchinson TA, Kramer MS, Feinstein AR (1979) An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians. J Am Med Assoc 242: 1991-4.

Louik C, Lacouture PG, Mitchell AA, Kauffman R, Lovejoy FH, Yaffe SJ, Shapiro S (1985) A study of adverse reaction algorithms in a drug surveillance program. Clin Pharmacol Ther 38: 183-7.

MacDonald MG, MacKay BR (1964) Adverse drug reactions: experience of Mary Fletcher Hospital during 1962. J Am Med Assoc 190: 1071-4.

McEwen J (1999) Adverse reactions—a pesonal view of their history. Int J Pharm Med 13: 269-77.

Meyboom RHB (1998) Causality assessment revisited. Pharmacoepidemiology and Drug Safety 7: S63-S65.

Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ (1997a) Principles of signal detection in pharmacovigilance. Drug Safety 16: 355-65.

Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR (1997b) Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety 17: 374-89.

Meyboom RHB, Royer RJ (1992) Causality classification at pharmacovigilance centres in the European Community. Pharmacoepidemiology and Drug Safety 1: 87-97.

Michel DJ, Knodel LC (1986) Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 43: 1709-14.

Miremont G, Haramburu F, Begaud B, Pere JC, Dangoumau J (1994) Adverse drug reactions: physicians' opinions versus a causality assessment method. Eur J Clin Pharmacol 46: 285-9.

Naranjo CA (1986) A clinical pharmacologic perspective on the detection and assessment of adverse drug reactions. Drug Inf J 20: 387-93.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-45.

Naranjo CA, Kwok MCO, Lanctot, KL, Zhao HP, Spielberg SP, Shear NH (1994) Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach. Clin Pharm Ther 56: 564-75.

Naranjo CA, Lanctot KL (1991) Recent developments in computer-assisted diagnosis of putative adverse drug reactions. Drug Safety 6: 315-22.

Naranjo CA, Lanctot KL (1993) Bayesian evaluation of sequential cases of neutropenia. Pharmacoepidemiol-ogy and Drug Safety 2: S1 -S6.

Naranjo CA, Lanctot KL, Lane DA (1990a) The Bayesian differential diagnosis of neutropenia asso ciated with antiarrhythmic agents. J Clin Pharmacol 30: 1120-7.

Naranjo CA, Lane D, Ho-Asjoe M, Lanctot KL (1990b) A Bayesian assessment of idiosyncratic adverse reactions to new drugs: Guillain-Barre Syndrome and zimeldine. J Clin Pharmacol 30: 174-80.

Pere JC, Begaud B, Haramburu F, Albin H (1986) Computerized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 40: 451-61.

Rossi AC, Knapp DE (1984) Discovery of new adverse drug reactions. A review of the Food and Drug Administration's Spontaneous Reporting System. J Am Med Assoc 252: 1030-3.

Rothman KJ, Greenland S (1998) Causation and causal inference. In: Rothman KJ, Greenland S, eds., Modern Epidemiology. Philadelphia, PA: LippincottRaven, pp. 7 -28.

Schmidt LG, Dirshedl P, Grohmann R, Scherer J, Wunderlich O, Muller-Oerlinghausen B (1986) Consistency of assessment of adverse drug reactions in psychiatric hospitals: a comparison of an algorithmic and an empirical approach. Eur J Clin Pharm 30: 199-204.

Seidl LG, Thornton GF, Cluff LE (1965) Epidemiological studies of adverse drug reactions. Am J Pub Health 55: 1170-5.

Sicker Th, Hoffmann A, Hoffmann H (1998) Individual case assessment of venous thromboembolic events suspected to be associated with combined oral contraceptives. Experience of reevaluating individual case histories on Valette®. Pharmacoepidemiology and Drug Safety 7 (Suppl): S109-S10.

Stephens MDB (1999) Causality assessment and signal recognition. In: Stephens MDB, Talbot JCC, Routle-dge PA, eds., Detection of New Adverse Drug Reactions. London: Macmillan Reference Ltd (UK), pp. 297-318.

Tubert P, Begaud B, Haramburu F, Pere JC (1991) Spontaneous reporting: how many cases are required to trigger a warning? Br J Clin Pharmacol 32: 407-8.

Turner WM (1984) The Food and Drug Administration algorithm. Special workshop-regulatory. Drug Inf J 118: 259-66.

Venning GR (1983) Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? Br Med J 286: 199-202.

Venulet J (1984) Aspects of standardization as applied to the assessment of drug-event associations. Drug Inf J 18: 199-210.

Venulet J (1985) Informativity of adverse drug reactions data in medical publications. Drug Inf J 19: 357-65.

Venulet J (1986) Incomplete information as a limiting factor in causality assessment of adverse drug reactions and its practical consequences. Drug Inf J 20: 423-31.

Venulet J (1988) Possible strategies for early recognition of potential drug safety problems. Adv Drug React Ac Pois Rev 1: 39-47. Venulet J (1992) Role and place of causality assessment. Pharmacoepidemiology and Drug Safety 1: 225-34.

Wartenberg D, Greenberg M (1993) Solving the cluster puzzle: clues to follow and pitfalls to avoid. Stat Med 12: 1763-70.

Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook


Post a comment